NCT00006013View on ClinicalTrials.gov

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

January 31, 2003

Study Completion Date

January 31, 2003

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

semaxanib

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

60637-1470

University of Chicago Cancer Research Center, Chicago

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER

NCT00006013 - SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter